TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03326791
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trombyl 160 mg once daily
Study: NCT03326791
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet daily
Study: NCT02956486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT00006337
Drug: IV Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00583531
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 2 grams TID in sachets for 4 weeks
Study: NCT02499250
Drug: Optimal medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Study: NCT02049307
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01145183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo daily dosing
Study: NCT02550366
Drug: MRI Contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI Contrast
Study: NCT00197730
Drug: Multivitamins - vitamins B complex, C and E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
Study: NCT00197730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
Study: NCT00982072
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 1mg/kg maximum 60mg od
Study: NCT03384966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for subcutaneous administration.
Study: NCT05410314
Drug: Myo-Inositol and D-Chiro-Inositol (MIC)
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
Study: NCT00137449
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
Study: NCT01892189
Drug: TAK-063 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 placebo-matching tablets
Study: NCT00853684
Drug: OXCE
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
Study: NCT01266980
Drug: Inhaled FF/ GW642444M (200/25mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
Study: NCT02033408
Drug: AB (antibiotics)
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.
Study: NCT02033408
Drug: CS (corticosteroids) Only
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks
Study: NCT01189760
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
Study: NCT01712373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: it is placebo
Study: NCT03452345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Normal saline)
Study: NCT03395093
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
Study: NCT03482232
Drug: Non-steroidal anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
Study: NCT03482232
Drug: Antimicrobial agent
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
Study: NCT03482232
Drug: Lipid-lowering drug
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
Study: NCT03482232
Drug: Antimicrobial agent
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotics for pharyngitis (infants)
Study: NCT03482232
Drug: Mucolytic
Normalized name: MUCOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
Study: NCT03482232
Drug: Ibuprofen and paracetamol
Normalized name: Ibuprofen and paracetamol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with ibuprofen and paracetamol (infants)
Study: NCT02171728
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03409198
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT03409198
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT00520338
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. placebo~2. celecoxib 400 mg oral single dose
Study: NCT01991873
Drug: Maintenance Chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01991873
Drug: mFOLFOX6 (Within re-induction phase)
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02594072
Drug: Zoladex ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
Study: NCT03208790
Drug: Nigella sativa buccal tablets 10mg
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
Study: NCT03208790
Drug: Nigella sativa buccal tablets 5mg
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
Study: NCT03208790
Drug: Placebo buccal tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules with the same color and form as the active ones but without active ingredient will be given to the patients
Study: NCT01288794
Drug: Diuretics plus human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
Study: NCT01288794
Drug: Diuretics (standard medical treatment)
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive standard medical treatment (diuretics)
Study: NCT02937519
Drug: induction Chrono-chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937519
Drug: induction Routine-chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01454869
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
Study: NCT01454869
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
Study: NCT00035464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets, twice a day for 6 months
Study: NCT00754572
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg oral or parenteral weekly.
Study: NCT01505088
Drug: Prednisolone Acetate (1%) Eyedrops
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone phosphate (DB14631)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate (1%) eyedrops
Study: NCT01505088
Drug: Placebo Eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Eyedrops
Study: NCT00347269
Drug: Psychotropic medication optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
Study: NCT03577470
Drug: D/C/F/TAF Fixed-Dose Combination (FDC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
Study: NCT04249037
Drug: Standard initiation of antiretroviral therapy (ART)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
Study: NCT02786329
Drug: TIVA+placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
Study: NCT03176992
Drug: SURGICEL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
Study: NCT00528099
Drug: IMA-026
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
Study: NCT00807807
Drug: Placebo Folic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo folic acid once a day for 6 weeks
Study: NCT01574612
Drug: acyclovir/hydrocortisone cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream applied topically to lesion five times daily for five days
Study: NCT04270019
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard solution of sterile normal saline.
Study: NCT02262169
Drug: Placebo caplet of DLBS2411
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo caplet of DLBS2411, twice daily
Study: NCT02262169
Drug: DLBS2411
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 DLBS2411 caplet 250 mg, twice daily
Study: NCT03340779
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
Study: NCT01154933
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline sq
Study: NCT01687426
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye daily four times a day for 14 days
Study: NCT00123942
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01894165
Drug: ALXN1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
Study: NCT01894165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
Study: NCT04248452
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04248452
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04248452
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04248452
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01107496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules administered orally 3 times a day
Study: NCT00392288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI over twelve weeks
Study: NCT00745875
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg oral tablet, once daily
Study: NCT00745875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg oral tablet, once daily
Study: NCT04576455
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study: NCT02930551
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02935036
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical product
Study: NCT03862950
Drug: Placebo Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid or capsules given in parallel to active medication.
Study: NCT02771158
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered to double blind the study
Study: NCT03345550
Drug: Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
Study: NCT03345550
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
Study: NCT00181246
Drug: Transdermal Fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01251055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch
Study: NCT02132260
Drug: Naftin® (Naftifine Hydrochloride) Cream 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
Study: NCT02132260
Drug: Placebo Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
Study: NCT04691115
Drug: AM1476
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM1476 Capsules
Study: NCT04691115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules
Study: NCT06638749
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of normal saline
Study: NCT00936650
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
Study: NCT03653546
Drug: AZD3759
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3759 200mg PO BID.
Study: NCT00835549
Drug: OMNICEF® for oral suspension 250 mg/5mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 250 mg/5mL, single-dose non-fasting
Study: NCT00835042
Drug: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 15/25 mg
Study: NCT00835042
Drug: UNIRETIC® 15/25 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 15/25 mg
Study: NCT02592863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take placebo 3 times per day for 12 weeks
Study: NCT03228732
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
Study: NCT03228732
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
Study: NCT03228732
Drug: Fluoxetine and DHEA
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
Study: NCT03453541
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
Study: NCT01602913
Drug: Pravastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
Study: NCT03398291
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
Study: NCT01602913
Drug: Pravastatin and paroxetine combined
Normalized name: pravastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
Study: NCT00803855
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, single dose
Study: NCT03890094
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
Study: NCT01787747
Drug: AVP-786 Dose 1/Q Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01787747
Drug: AVP-786 Dose 1/Q Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01787747
Drug: AVP-786 Dose 2/Q Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00581919
Drug: Bort, Dex, and Dox with ALCAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
Study: NCT02800785
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
Study: NCT00200746
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amino Acid Arginine
Study: NCT01344655
Drug: Atimos®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 μg pMDI
Study: NCT01344655
Drug: Serevent™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 25 µg pMDI
Study: NCT01344655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00854737
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill